AxioNovo

AxioNovo is a clinical-stage biopharmaceutical company focused on developing novel treatments for hematological malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The company's lead candidate, AXN-042, is a proprietary oral formulation of omacetaxine mepesuccinate, a protein synthesis inhibitor that is currently FDA-approved in a subcutaneous form for chronic myeloid leukemia. By transitioning to an oral delivery method, AxioNovo seeks to optimize the therapeutic window and improve patient compliance for broader oncology indications. The company leverages deep expertise in hematology to advance its pipeline through clinical trials in collaboration with leading cancer centers such as MD Anderson.